A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Clinical trial NCT03561259 · UNKNOWN

Trial details

NCT number: NCT03561259
Sponsor: Jubilant DraxImage Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroblastoma Neuroectodermal Tumors Neoplasms

Start date: 2019-10-21
Primary completion: 2023-12-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.